KOSDAQBiotech & Pharma347850

D&D Pharmatech

₩35,950▼ 1.51%2026-11-18 close
Market Cap
₩1.7T
Turnover
₩15.1B
Volume
410K
Shares out.
46M
PER
—
PBR
—
EPS
-₩735
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

MASH licensing decides D&D Pharmatech's next phase

D&D Pharmatech remains loss-making, with KRW 4.3 billion in 2025 revenue and KRW 34 billion in operating loss, and the licensing outcome for its MASH candidate DD01 is now the key variable after a partner discontinued an obesity asset.

  1. 1

    2025 revenue fell 62.4% year on year to KRW 4.3 billion, and operating loss widened to KRW 34 billion.

  2. 2

    The four quarters to Q3 2026 carried a combined controlling-shareholder net loss of KRW 32.9 billion, and Q3 2026 revenue was KRW 156 million.

  3. 3

    After Pfizer halted development of the partnered obesity candidate MET-224o in early August 2026, the DD01 licensing deal became the central task.

  4. 4

    In the Phase 2 trial, the 48-week MASH resolution rate was 62.5% in the DD01 arm versus 5.3% on placebo.

  5. 5

    In early November 2026, rights to key pipeline assets moved from the US subsidiary Neuraly to the parent, consolidating licensing negotiations at the listed company.

02

Business structure

D&D Pharmatech is a peptide-based drug R&D company founded in 2014 and listed on KOSDAQ in 2024. Its origin lies in obesity candidates built on its in-house oral conversion platform ORALINK, and between 2023 and 2024 it out-licensed seven candidates to US partner Metsera.

Pfizer acquired Metsera in November 2025, and in early August 2026 Pfizer decided to discontinue MET-224o, one of the oral obesity candidates. The company positions DD01, its MASH candidate that met its Phase 2 endpoints, as its core asset and is focusing on securing a partner and entering Phase 3.

The US subsidiary Neuraly has led development of TLY012 (a fibrosis drug in US Phase 1) and NLY01 (a neurodegenerative candidate that completed North American Phase 2 in Parkinson's disease and received US Phase 2 clearance in Alzheimer's disease).

Under an asset transfer agreement disclosed in early November 2026, the patents and development and commercialization rights for TLY012, NLY01 and NLY12 moved from Neuraly to the parent, for USD 3.31 million (about KRW 4.4 billion). Revenue is concentrated in research services and licensing income.

Consolidated revenue for the first half of 2026 was KRW 790.84 million, made up of KRW 257.54 million from DD01 licensing, KRW 370.96 million from an imaging biomarker license, and KRW 162.33 million from obesity-drug research services, according to the half-year report dated August 14, 2026.

The research services contract with Pfizer for oral peptide dual-agonist formulation development is worth KRW 1.83 billion, with a supply period from April 14 to November 30, 2026.

Most existing GLP-1 products are injectables, and the company highlights its oral candidates as a differentiator, but according to the company itself, oral obesity drugs have already reached the global market.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1B-₩6.2B−640.5%
2025Q4₩1B-₩10.4B−1051.6%
2026Q1₩100M-₩11.1B−8636.7%
2026Q2₩700M-₩9.9B−1492.3%
2026Q3₩200M-₩13.6B−8705.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩18.7B-₩13.5B₩3.9B−72.2%8.4%43.4%
2024₩11.4B-₩25B-₩28.6B−218.7%−40.8%40.1%
2025₩4.3B-₩34B-₩23.6B−791.0%−29.6%23.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed basis, revenue fell from KRW 18.7 billion in 2023 to KRW 11.4 billion in 2024 (down 38.8% year on year) and to KRW 4.3 billion in 2025 (down 62.4% year on year), a two-year consecutive decline from 2024 through 2025. Among 2023 to 2025, 2023 was the largest year and 2025 the smallest.

The company attributed the 2025 drop to joint R&D income falling from KRW 7.1 billion to KRW 3.7 billion, and to the base effect of KRW 2.7 billion in milestone revenue recognized in the prior year.

Operating loss was KRW 13.5 billion in 2023, KRW 25 billion in 2024 and KRW 34 billion in 2025, which is three consecutive years of losses, with the losses widening in 2024 and 2025. Operating margin moved from -72.2% in 2023 to -218.7% in 2024 and -791.0% in 2025, as costs did not keep pace with the shrinking revenue.

First-half 2026 consolidated R&D spending of KRW 13.09 billion was more than sixteen times revenue for the same period, according to the half-year report, which shows how heavily the loss structure depends on R&D outlays.

Controlling-shareholder net income went from KRW 3.93 billion in 2023 to a controlling-shareholder net loss of KRW 28.6 billion in 2024, a swing into loss, and narrowed to a loss of KRW 23.6 billion in 2025.

Net income including non-controlling interests is a separate figure, a net loss of KRW 24 billion in 2025, so the two measures should be read apart. Operating cash flow was -KRW 9.12 billion in 2023, -KRW 21.8 billion in 2024 and -KRW 21.1 billion in 2025.

Quarterly revenue went from KRW 969 million in Q3 2025 and KRW 990 million in Q4 2025 to KRW 129 million in Q1 2026, recovered to KRW 662 million in Q2, and fell back to KRW 156 million in Q3 2026. Q3 2026 operating loss of KRW 13.6 billion was wider than a year earlier.

Q4 2025 posted a controlling-shareholder net income of KRW 1.81 billion, a swing into profit, but losses resumed for three consecutive quarters from Q1 2026 through Q3 2026, and the combined controlling-shareholder net loss over the last four quarters is KRW 32.9 billion.

The debt ratio declined from 43.4% in 2023 to 40.1% in 2024 and 23.5% in 2025, with year-end 2025 total equity of KRW 79 billion, controlling-shareholder equity of KRW 79.5 billion and total liabilities of KRW 18.6 billion.

05

Industry analysis

MASH (metabolic dysfunction-associated steatohepatitis) can progress to liver fibrosis, and the company has framed DD01's Phase 2 results against competing drugs.

In data released on May 27, 2026, the proportion of patients with MASH resolution without fibrosis worsening at week 48 was 62.5% in the DD01 arm versus 5.3% on placebo, and the proportion with fibrosis improvement without MASH worsening was 50.0% versus 15.8%. Achieving both endpoints together was 37.5% versus 5.3%.

According to a Daily Invest report, some securities analysts described efficacy after only 12 weeks of dosing as superior to competing drugs given over 24 to 72 weeks. The same report pointed to the company's oral pipeline as a differentiator, since most existing GLP-1 products were developed as injectables.

The company's own framing is that oral obesity drugs have already reached the global market, and opinions differ on whether Pfizer's halt of MET-224o signals a broader industry trend. The company described the decision as a partner's strategic choice that leaves the platform and research asset values unchanged.

Industry commentary holds that whether the efficacy replicates across the full patient population will be the final gate for licensing talks. At this stage of the cycle, D&D Pharmatech is pre-commercial, with revenue relying on research services and licensing milestones, and it has no stable product revenue base.

06

Outlook

The core task the company has stated is licensing DD01. According to a Deal Site report, the company intends to secure a partner for DD01, which succeeded in Phase 2, and focus on entering Phase 3.

A June 2026 report said the final study report (CSR), covering all evaluable patients, was scheduled for release in Q3 2026, and that whether the results replicate across the full patient population is seen as the gate for licensing talks.

The company said it would use part of the KRW 226.5 billion convertible bond issued in April 2026 to advance other research assets. After the Neuraly rights consolidation, TLY012 was presented as the next pipeline asset expected to enter the clinic in 2027.

NLY01 has completed North American Phase 2 in Parkinson's disease and received US Phase 2 clearance in Alzheimer's disease. The Pfizer research services supply period ends on November 30, 2026, and whether a follow-on contract is signed will determine the continuity of research-service revenue.

As the first-half 2026 revenue mix shows, near-term revenue depends on one-off licensing income and research services. The next periodic report is the 2026 annual report, and the annual operating loss and whether Q4 revenue is recognized there will be the next confirmation points.

07

Valuation

PER
—
PBR
—
ROE
-34.2%
EPS
-₩735
BPS
—
Dividend per share
₩0

Earnings-based multiples do not currently apply. Because the combined controlling-shareholder net loss over the last four quarters is KRW 32.9 billion, the P/E ratio is not calculated.

On an asset basis, the market capitalization is far larger than year-end 2025 total equity of KRW 79 billion, so the stock carries a large premium to net assets. That gap reflects a large weight on DD01 licensing that is not yet contracted and on expectations for the pipeline.

The dividend yield is 0%, below the industry average dividend yield. After the KRW 226.5 billion convertible bond issued in April 2026, total liabilities at the first-half 2026 period end were KRW 185.8 billion, a sharp change in the capital structure compared with KRW 18.6 billion at year-end 2025.

Conversion of the bonds would add shares, so this is an item to review alongside per-share value comparisons. Because the share price has moved widely, this section sticks to factual comparisons rather than historical trading bands.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Differentiated DD01 Phase 2 data

At week 48, the MASH resolution rate was 62.5% in the DD01 arm versus 5.3% on placebo. The fibrosis improvement rate was 50.0% versus 15.8%, and meeting both endpoints was 37.5% versus 5.3%. Average liver fat fell 68.2%, while the placebo arm fell 7.8%. Some securities analysts described the efficacy after a short dosing period as superior to competing drugs.

Licensing income now accrues to the parent

In early November 2026, the patents and rights for TLY012, NLY01 and NLY12 moved from Neuraly to the parent. As a result, the parent becomes the contracting party for future US trials and licensing deals, and it recognizes upfront payments, milestones and royalties directly.

The transfer structure carries no separate recurring technology fee owed to the subsidiary. The company described the move as a way to lead licensing talks with global partners more directly.

Cash holdings and research capacity

The 2026 half-year report shows KRW 12.2 billion in cash and equivalents, KRW 140 billion in short-term financial products and KRW 90.4 billion in long-term financial products. R&D headcount stood at 39, including 21 PhD-level staff, giving the company in-house clinical capacity.

Collaboration with a large pharma company continues through the Pfizer formulation research services contract. Cash holdings rose sharply after the convertible bond issuance compared with year-end 2025.

09

Bear factors

Partner discontinued an obesity asset

In early August 2026, Pfizer decided to discontinue MET-224o, an oral obesity candidate held by Metsera that was one of the assets D&D Pharmatech had out-licensed. Reports said the market capitalization fell sharply from its peak after the news.

The company said the decision was a partner's strategic choice and that the platform and research asset values are intact. Still, when development moves to another party, the timing of royalties and milestones becomes uncertain.

Thin revenue base

2025 revenue was KRW 4.3 billion, down 62.4% year on year, and Q3 2026 revenue was KRW 156 million, down 83.9% from a year earlier. Losses have persisted for five consecutive quarters, and Q3 2026 operating loss was KRW 13.6 billion.

The combined controlling-shareholder net loss over the last four quarters was KRW 32.9 billion. As a pre-commercial company, R&D spending continues to drive the bottom line.

Convertible bond dilution and higher liabilities

The company issued a KRW 226.5 billion convertible bond in April 2026. When conversion requests for the first and second tranches were disclosed in June 2026, about 1.42 million shares were set to list, and the stock fell more than 13% over two days. Conversion increases the share count.

First-half 2026 total liabilities of KRW 185.8 billion compare with KRW 18.6 billion at year-end 2025. Whether the conversion shares are absorbed by the market is cited as a variable for the share price.

10

Risk factors

Clinical reproducibility risk

The DD01 Phase 2 results are based on week-48 biopsy data. Whether the same efficacy holds across the full evaluable population in the final study report is the key issue. A Phase 3 program requires large costs and time, and regulatory requirements are not yet settled. Long-term safety data will accumulate only in Phase 3, which limits what current data can show.

Licensing timing and terms risk

Whether and when a DD01 licensing deal is signed is not settled. The company's listing-stage registration statement named the risk that licensing revenue may not materialize among its core risks. A partner has already halted a previously licensed asset, so milestone receipt is not assured even after signing. Contract terms will shape the size and timing of revenue the company recognizes.

Funding and dilution risk

Operating cash flow was -KRW 9.12 billion in 2023, -KRW 21.8 billion in 2024 and -KRW 21.1 billion in 2025. First-half 2026 R&D spending of KRW 13.09 billion was well above consolidated revenue for the same period.

Cash and financial products were on hand at the half-year end, but convertible bond conversions and any further fundraising could affect per-share value.

11

What to watch next

  1. November 30, 2026

    End of the supply period for the Pfizer research services contract on oral peptide dual-agonist formulation. Whether a follow-on or extension is disclosed will show whether research-service revenue continues.

  2. By March 31, 2027

    Deadline for the 2026 annual report. Full-year 2026 revenue, operating loss and fourth-quarter results will be confirmed in this periodic filing. The next confirmation point is the full-year operating margin.

  3. 2027

    Expected start of clinical entry for the next pipeline asset TLY012. Whether it enters the clinic is the first checkpoint for pipeline diversification.

  4. Timing not set

    Whether a DD01 licensing agreement is signed. The company has said it aims to secure a partner before entering Phase 3, and whether the terms and upfront amount are disclosed is the next checkpoint.

12

Overall view

D&D Pharmatech reported KRW 4.3 billion in 2025 revenue and KRW 34 billion in operating loss, and its obesity pipeline has lost an external development partner, shifting the focus to licensing its MASH candidate DD01.

Strengths include DD01 Phase 2 results in which MASH resolution and fibrosis improvement rates clearly exceeded placebo, the transfer of Neuraly's rights to the parent so that licensing income is booked directly there, and a holding of cash and financial products at the first-half 2026 period end.

Weaknesses include revenue declines since 2024, five consecutive quarters of operating losses, a combined controlling-shareholder net loss of KRW 32.9 billion over the last four quarters, and dilution and higher liabilities from the convertible bond.

The strengths and weaknesses hinge on a single variable, whether the licensing deal is signed. A deal could change the revenue and cash flow structure, while a failure would prolong the current loss structure.

The next checkpoints are the end of the Pfizer research services supply period on November 30, 2026, the 2026 annual report due by March 31, 2027, and whether TLY012 enters the clinic in 2027.

This report offers no investment opinion or target price and is limited to a factual summary based on disclosures and press reports.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. m.news.nate.com
  2. dealsite.co.kr
  3. alphasquare.co.kr
  4. comp.wisereport.co.kr
  5. comp.fnguide.com
  6. m.sedaily.com
  7. biotimes.co.kr
  8. biobookmedia.com
  9. smedaily.co.kr
  10. news.nate.com
  11. dailyinvest.kr
  12. investing.com
  13. iprovest.com
  14. alphadistill.com
  15. newspim.com
  16. datatooza.com
  17. newswell.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis